Severe thrombocytopenia is a rare but life-threatening side effect of cytotoxic chemotherapy for which risk factors are not well known. Our objective was to delineate a risk model for chemotherapy-induced thrombocytopenia requiring platelet transfusions in cancer patients. Univariate and multivariate analysis of risk factors for chemotherapy-induced thrombocytopenia requiring platelet transfusions were performed on the cohort of the 1,051 patients (CLB 1996) treated with chemotherapy in the Department of Medicine of the Centre Léon Bérard (CLB) in 1996. In univariate analysis, performance status (PS) greater than 1, platelet count less than 150,000/μL at day 1 (d1) before the initiation of chemotherapy, d1 lymphocyte count ≤700/μL, d1 polymorphonuclear leukocyte count less than 1,500/μL, and the type of chemotherapy (high risk v others) were significantly associated (P < .01) with an increased risk of severe thrombocytopenia requiring platelet transfusions. Using logistic regression, d1 platelet count less than 150,000/μL (odds ratio [OR], 4.3; 95% confidence interval [CI], 1.9 to 9.6), d1 lymphocyte counts ≤700/μL (OR, 3.37; 95% CI, 1.77 to 6.4), the type of chemotherapy (OR, 3.38; 95% CI, 1.77 to 6.4), and PS greater than 1 (OR, 2.23; 95% CI, 1.22 to 4.1) were identified as independent risk factors for platelet transfusions. The observed incidences of platelet transfusions were 45%, 13%, 7%, and 1.5% for patients with ≥3, 2, 1, or 0 risk factors, respectively. This model was then tested in 3 groups of patients treated with chemotherapy used as validation samples: (1) the series of 340 patients treated in the CLB in the first 6 months of 1997, (2) the prospective multicentric cohort of 321 patients of the ELYPSE 1 study, and (3) the series of 149 patients with non-Hodgkin's lymphoma treated in the CLB within prospective phase III trials (1987 to 1995). In these 3 groups, the observed incidences of platelet transfusions in the above-defined risk groups did not differ significantly (P > .1) from those calculated in the model. This risk index could be useful to identify patients at high risk for chemotherapy-induced thrombocytopenia requiring platelet transfusions.

SEVERE THROMBOCYTOPENIA is a rare but life-threatening side effect of cytotoxic chemotherapy.1,2Until now, the management of severe thrombocytopenia has been curative, relying on platelet transfusions when platelet counts are less than 20,000/μL and/or in case of bleeding.3,4 There are several drawbacks for platelet transfusions, in particular the risk of viral transmission and resistance to platelet transfusions that occurs in 0% to 24% of patients requiring frequent platelet transfusions.5-7 

Interleukin-11 (IL-11), thrombopoietin/megakaryocyte growth and development factor (MGDF), IL-1, IL-3, and IL-6 have been reported to be capable of increasing platelet count, reducing platelet nadir, or decreasing the duration of platelet transfusions, therefore opening the possibility of a prophylaxis of severe thrombocytopenia in the near future.8-14 However, the incidence of platelet transfusions is low in a general population of cancer patients treated with conventional chemotherapy.2 It would therefore be useful to identify risk factors for platelet transfusions to select candidate patients for the prophylactic administration of thrombopoietic growth factors.

We report here a retrospective study of risk factors for chemotherapy-induced thrombocytopenia requiring platelet transfusions in the cohort of cancer patients treated in the Department of Medicine of the Centre Léon Bérard in 1996. A risk model for platelet transfusions was delineated and then validated in 3 distinct series of patients.

Criteria for patients selection.

The method used in this study was to delineate a risk index for severe thrombocytopenia requiring platelet transfusions in a retrospective series and to validate this index in 3 distinct series of patients. Four distinct cohorts of patients are thus considered in this study.

In all 4 series, the selection criteria for the patients were identical and as follows. Patients were to be more than 17 years of age. Patients with leukemia, in particular chronic lymphocytic leukemia, were excluded, because of the possible contamination of peripheral blood by malignant cells. Patients receiving chemotherapy regimens administered daily were excluded. Patients were not to be treated concomitantly with cytokines (ie, interferon, IL-2, or others). Massive chemotherapy regimens, ie, regimens requiring bone marrow or peripheral blood stem cell reinjection, were excluded. Each patient was analyzed for only 1 course of chemotherapy in the 4 series.

The retrospective group of 1996 (CLB 1996) comprised all patients treated with chemotherapy in the Department of Medicine of the Centre Léon Bérard in 1996. That year, 3,223 courses of chemotherapy were administered to 1,116 patients matching the inclusion criteria. Every patient was analyzed only for his first course of chemotherapy administered in the Centre Léon Bérard in 1996. Histology, primary tumor site, chemotherapy regimen, sex, age, performance status (PS), blood cell count at day 1 (d1) just before the administration of chemotherapy, as well as platelet transfusions after the studied course were collected. Patients with missing blood cell count at day 1 (n = 65) were excluded. Of the 1,116 patients, 1,051 (94%) were therefore analyzed (Table 1). The risk model was established in this retrospective series.

Table 1.

Characteristics of Patients

CLB 1996 (n = 1,051)CLB 1997 (n = 312) ELYPSE 1 (n = 295) CLB-NHL (n = 149)Total (n = 1,807)
No. of Patients % No. of Patients % No. of Patients % No. of Patients % No. %
Median age (range)  55 (18-86)  56 (18-85)  58 (18-86)  70 (27-93)  
Age (yr)  
 <60  655 62  179  57  167* 57  37  25  1,038 58  
 ≥60  396  38  133  43  123* 43 112  75  764  42  
Sex  
 F  567  54  161 52  178  60  68  46  974  54  
 M  484 46  151  48  117  40  81  54  833  46 
Diagnostic  
 Carcinoma  
  Breast  247  24  78 25  99  34  0  0  424  23  
  Colon-rectum 96  9  16  5  50  17  0  0  162  
  Ovary  90  9  14  5  32  11  0  136  8  
  Head and neck  103  10  20  6  20 7  0  0  143  8  
  Other gastrointestinal  112 11  18  5  11  4  0  0  141  8  
  Lung cancer  61  6  22  7  8  3  0  0  91  
 Lymphoma  93  9  37  12  21  7  149  100 300  17  
 Bone and soft tissue sarcoma  68  7  17 5  13  4  0  0  98  5  
 Germ cells tumors 32  3  15  5  7  2  0  0  54  
 Others  149  14  75  25  34  10  0  258  14  
High-risk chemotherapy-151 
 Yes  105  10 92  29  24  8  74  50  295  16  
 No 946  90  220  71  271  92  75  50  1,512 84  
Chemotherapy regimens  
 ACVBP/ECVBP  14  1  14 4  4  1  74  50  106  6  
 ADRIAMYCINE alone 27  3  13  4  0  0  0  0  40  
 CDDP-5FU  85  8  15  5  16  5  0  116  6  
 CDDP-NAV/CDDP-VP16  55  5  22  7  2  0  0  84  5  
 DHAP  24  2  7  0  0  0  0  31  2  
 FAC/FEC/AC  115  11 44  14  90  28  0  0  249  14 
 FUFOL/LV5FU2  71  7  14  5  47  15  0  132  7  
 MAID  11  1  7  2  2  1  0  20  1  
 mBACOD  0  0  0  0  0  15  10  15  1  
 TAXANES  124  12  29  29  9  0  0  182  10  
 CHOP  25  2  12 4  9  3  53  36  99  5  
 BEP/EP  30  17  5  7  2  0  0  54  3  
 NAVELBINE alone 74  7  15  5  0  0  0  0  89  
 CAP/CEP/CP  34  3  2  1  22  7  0  58  3  
 Other  362  34  101  36  71  24 7  5  541  30  
No. of chemotherapy course  
 1 766-152 78  306  98  130  44  149  100 1,351  78  
 ≥2  213-152 22  6  2  165 56  0  0  384  21  
Performance status  
 0-1 881  84  250  80  252  85  103  69  1,486 82  
 >1  170  16  62  20  43  15  46 31  321  18 
CLB 1996 (n = 1,051)CLB 1997 (n = 312) ELYPSE 1 (n = 295) CLB-NHL (n = 149)Total (n = 1,807)
No. of Patients % No. of Patients % No. of Patients % No. of Patients % No. %
Median age (range)  55 (18-86)  56 (18-85)  58 (18-86)  70 (27-93)  
Age (yr)  
 <60  655 62  179  57  167* 57  37  25  1,038 58  
 ≥60  396  38  133  43  123* 43 112  75  764  42  
Sex  
 F  567  54  161 52  178  60  68  46  974  54  
 M  484 46  151  48  117  40  81  54  833  46 
Diagnostic  
 Carcinoma  
  Breast  247  24  78 25  99  34  0  0  424  23  
  Colon-rectum 96  9  16  5  50  17  0  0  162  
  Ovary  90  9  14  5  32  11  0  136  8  
  Head and neck  103  10  20  6  20 7  0  0  143  8  
  Other gastrointestinal  112 11  18  5  11  4  0  0  141  8  
  Lung cancer  61  6  22  7  8  3  0  0  91  
 Lymphoma  93  9  37  12  21  7  149  100 300  17  
 Bone and soft tissue sarcoma  68  7  17 5  13  4  0  0  98  5  
 Germ cells tumors 32  3  15  5  7  2  0  0  54  
 Others  149  14  75  25  34  10  0  258  14  
High-risk chemotherapy-151 
 Yes  105  10 92  29  24  8  74  50  295  16  
 No 946  90  220  71  271  92  75  50  1,512 84  
Chemotherapy regimens  
 ACVBP/ECVBP  14  1  14 4  4  1  74  50  106  6  
 ADRIAMYCINE alone 27  3  13  4  0  0  0  0  40  
 CDDP-5FU  85  8  15  5  16  5  0  116  6  
 CDDP-NAV/CDDP-VP16  55  5  22  7  2  0  0  84  5  
 DHAP  24  2  7  0  0  0  0  31  2  
 FAC/FEC/AC  115  11 44  14  90  28  0  0  249  14 
 FUFOL/LV5FU2  71  7  14  5  47  15  0  132  7  
 MAID  11  1  7  2  2  1  0  20  1  
 mBACOD  0  0  0  0  0  15  10  15  1  
 TAXANES  124  12  29  29  9  0  0  182  10  
 CHOP  25  2  12 4  9  3  53  36  99  5  
 BEP/EP  30  17  5  7  2  0  0  54  3  
 NAVELBINE alone 74  7  15  5  0  0  0  0  89  
 CAP/CEP/CP  34  3  2  1  22  7  0  58  3  
 Other  362  34  101  36  71  24 7  5  541  30  
No. of chemotherapy course  
 1 766-152 78  306  98  130  44  149  100 1,351  78  
 ≥2  213-152 22  6  2  165 56  0  0  384  21  
Performance status  
 0-1 881  84  250  80  252  85  103  69  1,486 82  
 >1  170  16  62  20  43  15  46 31  321  18 

*Missing data: n = 5.

F0-151

See the Patients and Methods.

F0-152

Missing data: n = 72.

The risk model was then tested in 3 groups used as validation samples. The first group (CLB 1997) is the retrospective series of 340 patients treated in the Centre Léon Bérard during the first 6 months of 1997 and who had not received chemotherapy in the Department of Medicine of the Centre Léon Bérard in 1996. Every patient was analyzed only for his first course of chemotherapy administered in the Centre Léon Bérard in 1997. Only 312 of the 340 patients (92%) were included in the analysis because of missing data on blood cell count at day 1 (n = 28).

The second group (ELYPSE 1) is a multicentric prospective series of 321 patients treated with conventional chemotherapy in both general hospital (n = 13) and comprehensive cancer centers (n = 5): 84 patients (26%) were treated in cancer centers and 237 (74%) in general hospitals. Every participating physician had to include all his consecutive patients for 1 month between November 1995 and September 1996. Only 295 of the 321 patients (92%) were analyzed because of missing data for performance status (n = 24) or blood cell count at day 1 (n = 2). This series has been recently reported.15 

The third group (NHL-CLB) is the cohort of 149 non-pretreated patients with intermediate- or high-grade non-Hodgkin's lymphoma included in prospective multicentric phase III of the GELA group who received a first course of conventional chemotherapy regimen in the Centre Léon Bérard between 1987 and 1995. There were no missing data in this series and all patients were evaluated.

The characteristics of the patients in the 4 series are listed in the Table 1.

Indications of platelet transfusions.

Platelet transfusions adminstered for chemotherapy-induced thrombocytopenia within the 28 days after the course of chemotherapy was chosen as the end-point for this study. Criteria for platelet transfusions in the Centre Léon Bérard as well as for the physicians who participated to the ELYPSE 1 series were platelet count less than 20,000/μL or thrombocytopenia less than 50,000/μL with coagulation disorders and/or heparin therapy and/or with bleeding complications. Within the database, 4 patients with the above-described inclusion criteria (all in the CLB 1996 series) were not transfused with platelets, although they had platelet counts less than 20,000/μL. In all 4 cases, this decision was made by the physician because a rapid (<48 hours) death due to tumor progression was expected (and indeed occurred). The model presented here was not modified when these patients are considered as having had an event.

Chemotherapy regimens.

The chemotherapy regimens were separated in 2 subgroups according to the doses and the type of drugs administered. The criteria high-risk chemotherapy has been previously reported and refers to regimens containing either greater than 90 mg/m2 doxorubicin, greater than 90 mg/m2 epirubicin, greater than 100 mg/m2 cisplatin, greater than 9 g/m2ifosfamide, greater than 1 g/m2 cyclophosphamide, greater than 500 mg/m2 etoposide, or greater than 1 g/m2 cytarabine per course.15 16 The other subgroup of regimens included all other chemotherapy regimens.

Statistical analysis.

Risk factors for platelet transfusions were tested in univariate and multivariate analysis using the procedures of the SPSS 6.01 program (1994; SPSS, Inc, Chicago, IL). The correlation between a clinical or a biological parameter and the incidence of chemotherapy-induced thrombocytopenia requiring platelet transfusions was performed using the χ2 test or Fisher's exact test. A logistic regression including the parameters studied in the univariate analysis was performed using logistic program of SPSS. The forward regression procedure was used with a P value less than .05 for entry. Risk factors (eg, PS >1) and end-point (ie, platelet transfusions) were considered 0 if absent and 1 if present. This multivariate analysis was performed in the 1,051 patients of the CLB 1996 series. A risk model was established using the independent risk factors identified in this multivariate analysis. This risk model was then tested on the 3 distinct cohorts of patients.

Univariate analysis.

Fifty-six of the 1,051 patients (5.3%) of the CLB 1996 series received platelet transfusions because of severe thrombocytopenia within the 28 days after the administration of the course of cytotoxic chemotherapy. In univariate analysis, platelet count less than 150,000/μL immediately before the initiation of chemotherapy (d1), d1 polymorphonuclear leukocyte (PMN) count less than 1.500/μL, d1 lymphocyte count ≤700/μL, PS greater than 1, and the type of chemotherapy regimen (high risk v others) as previously defined (Patients and Methods) were found to be significantly correlated to the risk of platelet transfusions (Table 2). In contrast, age less than 60 years, sex, and number of previous courses of chemotherapy were not significantly correlated to the incidence of platelet transfusions (Table 2).

Table 2.

Risk Factors for Thrombocytopenia Requiring Platelet Transfusions

No. of Patients (%)Platelet Transfusions P
N%
Age (yr)  
 ≤60  655 (62)  37  5.6  
 >60 396 (38)  19  4.8  .32  
Sex  
 F  567 (54) 32  5.6  
 M  484 (46)  24  5  .36  
No. of chemotherapy courses* 
 1  766 (78)  43  5.6  
 2-6 185 (18)  6  3.2  
 ≥7  28 (4)  0  0  .19 
High-risk chemotherapy 
 Yes  105 (10)  11  10.5 
 No  946 (90)  45  4.8  .01  
Performance status 
 0-1  881 (84)  36  4.1  
 >1  170 (16)  20 11.8  <.01  
d1 platelet count  
 <150,000/μL 100 (9)  19  19.2  
 ≥150,000/μL  951 (91)  37 3.9  <.01  
d1 lymphocyte count  
 ≤700/μL 234 (22)  29  12.4  
 >700/μL  817 (78)  27 3.3  <.01  
d1 PMN count  
 <1,500/μL  26 (2) 5  19.2  
 ≥1,500/μL  1025 (98)  51  .009 
No. of Patients (%)Platelet Transfusions P
N%
Age (yr)  
 ≤60  655 (62)  37  5.6  
 >60 396 (38)  19  4.8  .32  
Sex  
 F  567 (54) 32  5.6  
 M  484 (46)  24  5  .36  
No. of chemotherapy courses* 
 1  766 (78)  43  5.6  
 2-6 185 (18)  6  3.2  
 ≥7  28 (4)  0  0  .19 
High-risk chemotherapy 
 Yes  105 (10)  11  10.5 
 No  946 (90)  45  4.8  .01  
Performance status 
 0-1  881 (84)  36  4.1  
 >1  170 (16)  20 11.8  <.01  
d1 platelet count  
 <150,000/μL 100 (9)  19  19.2  
 ≥150,000/μL  951 (91)  37 3.9  <.01  
d1 lymphocyte count  
 ≤700/μL 234 (22)  29  12.4  
 >700/μL  817 (78)  27 3.3  <.01  
d1 PMN count  
 <1,500/μL  26 (2) 5  19.2  
 ≥1,500/μL  1025 (98)  51  .009 

*Missing data (n = 72).

See the Patients and Methods.

Multivariate analysis.

A logistic regression to identify independent risk factors for platelet transfusions was performed among all the parameters tested in univariate analysis. The parameters identified as independent risk factors for platelet transfusions were PS greater than 1 (odds ratio [OR], 2.23; 95% confidence interval [CI], 1.22 to 4.11), d1 platelet count less than 150,000/μL (OR, 4.30; 95% CI, 1.93 to 9.61), d1 lymphocyte count ≤700/μL (OR, 3.37; 95% CI, 1.77 to 6.44), and high-risk chemotherapy regimens (OR, 3.38; 95% CI, 1.77 to 6.46; Table 3).

Table 3.

Logistic Regression of Risk Factors for Platelet Transfusions

β SE χ2POR 95% CI
Platelet transfusions  
 Intercept  3.94  .24  252 <.001  —  
 High-risk chemotherapy* 1.21  .38 10.1  .001  3.38  1.77-6.46  
 d1 lymphocyte count ≤700/μL  1.21  .30  156.1  .001  3.37  1.77-6.44 
 PS >1  0.80  .31  6.6  .01  2.23  1.22-4.11 
 d1 platelet count <150,000/μL  1.46  .32  20.3 <.001  4.30  1.93-9.61 
β SE χ2POR 95% CI
Platelet transfusions  
 Intercept  3.94  .24  252 <.001  —  
 High-risk chemotherapy* 1.21  .38 10.1  .001  3.38  1.77-6.46  
 d1 lymphocyte count ≤700/μL  1.21  .30  156.1  .001  3.37  1.77-6.44 
 PS >1  0.80  .31  6.6  .01  2.23  1.22-4.11 
 d1 platelet count <150,000/μL  1.46  .32  20.3 <.001  4.30  1.93-9.61 

*See the Patients and Methods.

Risk model.

To construct a simple algorithm for calculating the expected risk of platelet transfusions for each patient, the parameters PS greater than 1, high-risk chemotherapy, d1 lymphocyte count ≤700/μL, and d1 platelet count less than 150,000/μL were all given an arbitrary risk coefficient of 1. The risk index for a given patient was obtained by summing the coefficients of these 4 risk factors and therefore ranged from 0 to 4. For example, a patient with PS equal to 1, receiving a non–high-risk chemotherapy regimen with d1 lymphocyte count ≤700 /μL and d1 platelet count less than 150,000/μL, has a risk index of 2. Because patients with 4 risk factors represented only 0.17% of these patients (3 of 1,807), patients with 3 and 4 risk factors were pooled; 4 risk groups of patients were thus defined (Table 4). The calculated probability of platelet transfusions was 44.5% (95% CI, 37.3% to 51.8%) in patients with 3 or 4 risk factors, 13% (95% CI, 10.1% to 16.8%) for patients with 2 risk factors, 7% (95% CI, 4.9% to 9.9%) for patients with 1 risk factor only, and 1.5% (95% CI, 1.1% to 2.2%) for patients with none of these risk factors (Table 4).

Table 4.

Incidence of Platelet Transfusions in the 4 Groups According to the Risk Model

 Calculated Incidence (%; 95% CI) Observed Incidence 
Validation Series 
CLB 1996  CLB 1997 ELYPSE 1  CLB-NHL Total  
No.  % (95% CI)  No.  % (95% CI)  No.  % (95% CI)  No.  % (95% CI)  No.  % (95% CI)  
≥3 risk factors  44.5 (37-52)  9/20 45 (23-67)  4/12  33.3 (6-60)  0/2  0  4/8 50 (15-85)  17/423-150 40 (25-55)  
2 risk factors  13 (10-17)  14/109  12.8 (7-19)  4/41 9.8 (1-19)  3/18  17 (0-34)  5/29 17 (3-31)  26/197  13 (8-18)  
1 risk factor  7 (5-10)  24/330  7.3 (5-10)  3/122 2.5 (0-5)  5/73  7 (1-13)  2/75 3 (0-7)  34/600  5.3 (3.5-7)  
No risk factor 1.5 (1-2)  9/592  1.5 (0.5-2.5)  2/137  1.5 (0-3.5) 2/202  1 (0-2)  0/37  0  13/968 1.3 (0.5-2) 
 Calculated Incidence (%; 95% CI) Observed Incidence 
Validation Series 
CLB 1996  CLB 1997 ELYPSE 1  CLB-NHL Total  
No.  % (95% CI)  No.  % (95% CI)  No.  % (95% CI)  No.  % (95% CI)  No.  % (95% CI)  
≥3 risk factors  44.5 (37-52)  9/20 45 (23-67)  4/12  33.3 (6-60)  0/2  0  4/8 50 (15-85)  17/423-150 40 (25-55)  
2 risk factors  13 (10-17)  14/109  12.8 (7-19)  4/41 9.8 (1-19)  3/18  17 (0-34)  5/29 17 (3-31)  26/197  13 (8-18)  
1 risk factor  7 (5-10)  24/330  7.3 (5-10)  3/122 2.5 (0-5)  5/73  7 (1-13)  2/75 3 (0-7)  34/600  5.3 (3.5-7)  
No risk factor 1.5 (1-2)  9/592  1.5 (0.5-2.5)  2/137  1.5 (0-3.5) 2/202  1 (0-2)  0/37  0  13/968 1.3 (0.5-2) 

The observed incidences of differences in platelet transfusions in risk groups ≥3, 2, 1, or 0 risk factors were not statistically different among the 4 series (χ2 = 2.09,P = .55 for comparison of patients with 3 or all risk factors; χ2 = 1.04, P = .79 for comparison of patients with 2 risk factors; χ2 = 5.77,P = .12 for comparison of patients with 1 risk factor; and χ2 = 0.85, P = .83 for comparison of patients with no risk factors).

F3-150

Including 3 patients with 4 risk factors.

Validation of the model.

This model was then tested in the 3 series of patients used as validation samples (Table 4).

In the CLB 1997 series, 4.2% (13 of 312) of the patients received platelet transfusions. The observed incidence of platelet transfusions was significantly different (P < 10−5) in patients with ≥3, 2, 1, or 0 risk factors (33.3%, 9.8%, 2.5%, and 1.5%, respectively; Table 4). A single patient had 4 risk factors and received platelet transfusions.

In the ELYPSE 1 series, 3.3% (10 of 295) of the patients received platelet transfusions. The observed incidence of platelet transfusions was significantly different (P = .001) in patients with ≥3, 2, 1, or 0 risk factors (0%, 17%, 7%, and 1%, respectively; Table 4). Of note, although none of the 2 patients with ≥3 risk factors were transfused with platelets, their nadir of platelets were 25,000/μL and 35,000/μL, respectively.

In the CLB-NHL series, 7.4% (11 of 149) of the patients received platelet transfusions. The observed incidence of platelet transfusions was significantly different (P < 10−5) in patients with ≥3, 2, 1, or 0 risk factors (50%, 17%, 3%, and 0%, respectively; Table 4).

The observed incidence of platelet transfusions in the 4 cohorts of patients studied were not significantly different (56 of 1,051,v 13 of 312, v 10 of 295, v 11 of 149; χ2 = 4.01, P = .25). The observed incidences of platelet transfusions in risk group ≥3, 2, 1, or 0 were not significantly different among the 4 series (χ2 = 2.09,P = .55 for patients with ≥3 risk factors; χ2 = 1.04, P = .79 for patients with 2 risk factors; χ2 = 5.77, P = .12 for patients with 1 risk factor; and χ2 = 0.85, P = .83 for patients with no risk factor; Table 4).

Risk factors for patients not receiving high-risk chemotherapy.

Because it is well established that the risk of thrombocytopenia correlates to the dose of chemotherapy, we asked whether this model could be useful in the subgroup of patients who did not receive high-risk chemotherapy as defined in this study. This subgroup represented, respectively, 946, 220, 271, and 75 of the patients in the CLB 1996, CLB 1997, Elypse 1, and NHL-CLB series. Forty-five patients (4.7%) of the CLB 1996 series (4.7%) received platelet transfusions because of severe thrombocytopenia. A multivariate analysis was performed on this subgroup of 946 patients to identify independent risk factors for severe thrombocytopenia requiring platelet transfusion in these patients. Logistic regression again identified the same 3 independent risk factors for platelet transfusion: PS greater than 1 (OR, 2.14; 95% CI, 0.87 to 5.3), d1 platelet count less than 150,000/μL (OR, 4.3; 95% CI, 0.6 to 30), and d1 lymphocyte count ≤700/μL (OR, 3.15; 95% CI, 0.8 to 13). The observed incidences of platelet transfusions in patients with 0, 1, 2, and 3 of these risk factors (PS, lymphocyte counts, and platelet counts) were 1.5%, 8%, 13%, and 36%, respectively, in the CLB 1996 series. The observed incidences of platelet transfusions in risk group 3, 2, 1, or 0 were not significantly different among the 4 series (χ2 = 1.5,P = .46 for patients with 3 risk factors; χ2 = 1.92, P = .58 for patients with 2 risk factors; χ2 = 1.56, P = .66 for patients with 1 risk factor; and χ2 = 0.81, P = .84 for patients with no risk factor). These results confirm that the general model described in Table 4 is also efficient for patients not receiving high-risk chemotherapy.

Severe thrombocytopenia induced by cytotoxic chemotherapy is associated with a potential risk of toxic death due to bleeding and may require to delay the administration of chemotherapy. The objective of the present study was to identify risk factors for chemotherapy-induced thrombocytopenia requiring platelet transfusions. The number of platelet transfusions was chosen as the most relevant end-point, because these patients could benefit the most of a prophylactic treatment capable to prevent or reduce the incidence of severe thrombocytopenia.

Little is known on the risk factors for platelet transfusions after conventional chemotherapy. A search on the electronic database (Medline) using the MESH terms platelet transfusions, thrombocytopenia, chemotherapy, toxicity, and risk factors identified no report devoted to the analysis of individual risk factors for severe thrombocytopenia induced by conventional cytotoxic chemotherapy. Therefore, it was chosen to select clinical and biological factors that were potentially correlated to the incidence of hematological toxicity of chemotherapy according to our previous studies (age, sex, PS, number of previous courses, and blood cell counts).15,16 Day-5 lymphocyte count ≤700/μL, a major risk factor for febrile neutropenia, was not available in most patients; hence, the day-1 lymphocyte count ≤700/μL, which was less strongly correlated to hematological toxicity in previous studies, was therefore tested.16 

The risk model for chemotherapy-induced thrombocytopenia requiring platelet transfusions was established on the retrospective cohort of patients treated in the Department of Medicine of the Centre Léon Bérard in 1996. Each patient was analyzed only for his first course during the year. As expected, the incidence of platelet transfusions was low in this series of patients treated with conventional chemotherapy regimens (n = 56 [5.3%]). Four parameters were found to have an independent prognostic value for platelet transfusions, ie, platelet count less than 150,000/μL at d1, lymphocyte count less than 700/μL at d1, high-risk chemotherapy regimens, and PS greater than 1. It is noteworthy that, when a logistic regression was applied to all 3,223 chemotherapy courses administered in the Department of Medicine of the CLB in 1996, the same independent risk factors with a similar weight were identified, supporting the validity of this model (data not shown). These results show that 2 categories of parameters influence the incidence of chemotherapy-induced thrombocytopenia requiring platelet transfusions: (1) parameters reflecting clinical and biological status of patient (ie, PS and day-1 platelet and lymphocyte count) and (2) the type of chemotherapy regimen (high-risk chemotherapy as defined in our previous study).15 16 The relative weight of the independent risk factors being not significantly different, a simple risk model was established that delineates 4 risk groups with 0, 1, 2, and ≥3 of these risk factors. Importantly, this model also proved to be efficient to identify patients at high risk for severe thrombocytopenia requiring platelet transfusion among the subgroup of patients not receiving high-risk chemotherapy. Twenty-nine percent (5 of 17 among the 4 series) of patients not receiving high-risk chemotherapy but with all 3 other risk factors experienced severe thrombocytopenia requiring platelet transfusion, a notably high incidence for patients receiving conventional chemotherapy.

The cohort of high-risk patients (≥3 risk factors) represented less than 3% of all patients in these 4 series and comprised 19% (17 of 90) of the patients who required platelet transfusions in the 4 series. The intermediate-risk group (2 risk factors) with a 13% calculated incidence of platelet transfusions comprised 29% (26 of 90) of the patients transfused with platelets in the 4 series. Patients with a risk index ranging from 2 to 4 included, therefore, 48% (43 of 90) of the patients who require platelet transfusions after chemotherapy administration in the 1,807 patients of the 4 series, although they represented only 13% (239 of 1,807) of all patients.

A potential limit of this study is the heterogeneity of these series in terms of disease types and chemotherapy regimens. Indeed, the CLB 1996 and CLB 1997 series included patients with similar clinical characteristics. In contrast, the CLB-NHL series comprised only patients with non-Hodgkin's lymphoma receiving their first course of chemotherapy, and the ELYPSE 1 series was a multicentric prospective cohort of patients. Despite the differences in the characteristics of patients, the risk index proved efficient to distinguish patients with a high risk of platelet transfusions. The reproducibility of the results in the 3 groups used as validation samples as well as the large number of patients analyzed (n = 1,807) suggest that the risk model may be useful to identify patients at high risk for chemotherapy-induced thrombocytopenia requiring platelet transfusions in the general population of patients treated with conventional chemotherapy.

This model could distinguish a cohort of patients with such a high risk of platelet transfusions that a prophylactic administration of a platelet growth factor, such as MGDF or IL-11, could be both clinically justified and cost-effective.13 14 Randomized phase III studies could focus on the subgroup of high-risk patients (with or without the subgroup of 2 risk factors) to evaluate the prophylactic use of these platelet growth factors versus placebo.

The authors are indebted to Frederic Bouanchaud for his assistance.

APPENDIX Investigator List for the ELYPSE 1 Study

Dr Jean C. Balzon (CH, Saintes); Dr Jean-Yves Blay (CLB, Lyon); Dr A. Boutan-Laroze (CH, Argenteuil); Dr Jacques Brunot (Hôpital Desgenettes, Lyon); Dr Laurent Cany (Clinique de Francheville, Périgueux); Dr Capdeville (CH, Foix); Dr Y. Caudry (Clinique Tivoli, Bordeaux); Dr D. Celerier (CH, Bayonne); Dr Zahia Haddad/Dr Bruno Salles (CH, Châlon); Dr A. Le Cesne/Dr K. Fizazi (IGR, Villejuif); Dr M. Malet (CH, Pau); Dr Maugard (Centre R. Gauducheau, Nantes); Dr Mayeur (CH, A.Mignot, Le Chesnay); Dr Jean Mermet (Clinique Sainte-Marie, Chambery); Dr B Mongodin/Dr M. Zouai (CH, Montelimar); Dr Hubert Orfeuvre (CH, Bourg en Bresse); Dr Pierre-Yves Peaud (CH, Valence); Dr Ravaud (Institut Bergonié, Bordeaux); Dr D. Sevin (Polyclinique Ste Marguerite, Auxerre); Dr Jean-Philippe Suchaud (CHG, Roanne); Dr Song Vu Van (Lyon)

Supported by a grant from Roche (Neuilly, France) and from the Programme Hospitalier de Recherche Clinique (France).

Address reprint requests to J.Y. Blay, MD, Centre Léon Bérard, 28, rue Laënnec-69008, Lyon, France; e-mail:blay@lyon.fnclcc.fr.

The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" is accordance with 18 U.S.C. section 1734 solely to indicate this fact.

© 1998 by the American Society of Hematology.

1
Beutler
E
Platelet transfusions: The 20000/μL trigger.
Blood
81
1993
1411
2
Myers
CE
Clinical pharmacology of cancer chemotherapy
De Vita
VT
Hellman
S
Rosenberg
SA
Cancer: Principles and Practice of Oncology.
1989
1197
Lippincott
Philadelphia, PA
3
Gmur
J
Burger
J
Schanz
U
Fehr
J
Schaffner
A
Safety of stringent prophylactic platelet transfusions policy for patients with acute leukemia.
Lancet
338
1991
1223
4
Platelet Transfusion Therapy
JAMA
257
1987
1777
5
Schiffer
CA
Dutcher
JP
Aisner
J
Hogge
D
Wiernik
PH
Reilly
JP
A randomized trial of leukocyte-depleted platelet transfusion to modify alloimmunization in patients with leukemia.
Blood
62
1983
815
6
Sniecinski
I
O'Donnell
MR
Nowicki
B
Hill
LR
Prevention of refractoriness and HLA-alloimmunization using filtered blood products.
Blood
71
1988
1402
7
Van Marwijk
KM
Van Prooijen
HC
Moes
M
Bosmastants
I
Akkerman
JWN
Use of leukocyte-depleted platelet concentrates for the prevention of refractoriness and primary HLA alloimmunization: A prospective randomized trial.
Blood
77
1991
201
8
Smith
JW
Longo
DL
Alvord
WG
Janik
JE
Sharfman
WH
Gause
BL
Curti BD
SP
Holmlund
JT
Fenton
RG
The effect of treatment with interleukin-1a on platelet recovery after high-dose carboplatin.
N Engl J Med
328
1993
756
9
D'Hondt
V
Weynants
P
Humblet
Y
Guillaume
T
Canon
JL
Beauduin
M
Duprez
P
Longueville
J
Mull
R
Chatelain
C
Dose dependent IL-3 stimulation of thrombopoiesis and neutropoiesis in patients with small cell lung carcinoma before and following chemotherapy: A placebo-controlled randomized phase Ib study.
J Clin Oncol
11
1993
2063
10
D'Hondt
V
Humblet
Y
Guillaume
T
Baatout
S
Chatelain
C
Berliere
M
Longueville
J
Feyens
AM
de Greve
J
Van Oosterom
A
Thrombopoietic effect and toxicity of interleukin-6 in patients with recurrent ovarian cancer before and after chemotherapy: A multicentric placebo-controlled, randomized phase Ib study.
Blood
85
1995
2347
11
Gordon
MS
McCaskill-Stevens
WJ
Battiato
LA
Loewy
J
Loesch
D
Breeden
E
Hofman
R
Beach
KJ
Kuca
B
Kaye
J
Sledge GW Jr
A phase I trial of recombinant human interleukin-11 (Neumega rhIL-11 growth factor) in women with breast cancer receiving chemotherapy.
Blood
87
1996
3615
12
Basser
RL
Rasko
JE
Clarke
K
Cebon
J
Green
MD
Hussein
S
Alt
C
Menchaca
D
Tomita
D
Marty
J
Fox
RM
Begley
CG
Thrombopoietic effects of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) in patients with advanced cancer.
Lancet
348
1996
1279
13
Fanucchi
M
Glaspy
J
Crawford
J
Garst
J
Figlin
R
Sheridan
W
Menchaca
D
Tomita
D
Ozer
H
Harker
L
Effects of polyethylene glycol-conjugated recombinant human megakaryocyte growth and development factor on platelet counts after chemotherapy for lung cancer.
N Engl J Med
336
1997
404
14
Tepler
I
Elias
L
Smith JW
II
Hussein
M
Rosen
G
Chang
AY-C
Moore
JO
Gordon
MS
Kuca
B
Beach
K
Loewy
JW
Garnick
MB
Kaye
JA
A randomized placebo controlled trial of recombinant human Interleukin 11 in cancer patients with severe thrombocytopenia due to chemotherapy.
Blood
87
1996
3607
15
(abstr)
Blay
JY
Ray-Coquard
I
Mermet
J
Maugard
C
Ravaud
A
Malet
M
Cany
L
Salles
B
Mayeur
D
Boutan-Laroze
A
Sevin
D
Vuvan
S
Peaud
PY
Balzon
JC
Capdeville
D
Suchaud
JP
Celerie
D
Zouai
M
Mongodin
B
Caudry
Y
Chevreau
C
Biron
P
Le Cesne
A
ELYPSE 1: A multicentric prospective study of prognostic factors for febrile neutropenia after cytotoxic chemotherapy in general and cancer hospitals.
Proc Am Soc Clin Oncol
16
1997
56a
16
Blay
JY
Chauvin
F
Le Cesne
A
Anglaret
B
Lasset
C
Freyer
G
Philip
T
Biron
P
Early lymphopenia after cytotoxic chemotherapy as a risk factor for febrile neutropenia.
J Clin Oncol
14
1996
636
Sign in via your Institution